B7-33 (Relaxin Mimetic)
Also known as B7-33 · single-chain relaxin · RXFP1 agonist peptide
New
Reconstitution & dosing guide
10 mg vial — research phases, recon steps, and a live unit calculator.
Available sizes & price
Catalog only10mg x 10 vials
B7-33 · Not in current stock
$80 / vial
Prices per vial · Research use only · Not medical advice.
Single-chain H2-relaxin B-chain derivative that preferentially activates antifibrotic RXFP1–pERK signaling; retains organ antifibrosis benefits of serelaxin without full cAMP profile in key models.
How to picture it
A single-chain relaxin-mimetic aimed at RXFP1, researched for anti-fibrotic signaling — helping scarred, stiffened tissue reduce excess collagen and improve matrix flexibility. Picture a simplified relaxin message focused on "don't over-build scar." Heart and lung fibrosis research makes this one of the more hopeful structural-repair stories in the catalog.
Research focus & benefits
- Anti-fibrotic RXFP1/relaxin-pathway research
- Scar and matrix remodeling studies
- Cardiac and pulmonary fibrosis model interest
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
B7-33 is a minimized linear relaxin mimetic (B-chain residues 7–33 region) developed to simplify synthesis versus two-chain H2 relaxin. It shows poor cAMP potency in overexpressed HEK systems but equipotent antifibrotic MMP-2 induction in fibroblasts, and reverses fibrosis in heart and lung disease models. Importantly, unlike H2 relaxin, it did not promote prostate tumor growth in reported mouse work.
Mechanism
Functionally selective RXFP1 agonism biased toward pERK and antifibrotic MMP pathways; may engage RXFP1–AT2 receptor heterodimer signaling relevant to collagen degradation. Short serum half-life (~minutes) with lipidated analogs under study for longer PK.
Research uses
- Cardiac and pulmonary fibrosis regression models
- Vasoprotective / preeclampsia endothelial models
- Comparison vs serelaxin and ACE inhibitors in cardiomyopathy models
Research dosing notes
Preclinical mg/kg schedules. Human dosing not established.
Half-life / kinetics
~6 minutes in serum (unmodified); lipidated analogs longer
Common research routes
Reported considerations
- Unknown human adverse profile
- Short half-life may limit practicality
Contraindications / cautions
- Pregnancy (relaxin biology is reproductive)
- Hormone-sensitive conditions — specialist care
Common research stacks
- BPC-157
- TB-500
- SS-31
Legal / access note
Experimental antifibrotic research peptide. Not approved therapy.